Michael Dickinson
A5102014552- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- Histone Deacetylase Inhibitors Research
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Cutaneous lymphoproliferative disorders research
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Viral Infectious Diseases and Gene Expression in Insects
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Biomedical Ethics and Regulation
- T-cell and Retrovirus Studies
- Acute Lymphoblastic Leukemia research
- Integrated Circuits and Semiconductor Failure Analysis
- Construction Project Management and Performance
- Glioma Diagnosis and Treatment
- Immunotherapy and Immune Responses
The University of Melbourne
2015-2025
Peter MacCallum Cancer Centre
2016-2025
The Royal Melbourne Hospital
2009-2025
Memorial University of Newfoundland
2024
Moffitt Cancer Center
2021-2023
Moldova State University
2023
National Center for Advancing Translational Sciences
2023
Spectrum Health
2023
Mansoura University
2023
Horizon Health Network
2022
The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt first-line chemoimmunotherapy is poor.In this international, phase 3 trial, we randomly assigned, in a 1:1 ratio, that was to had no more than 12 months receive axicabtagene ciloleucel (axi-cel, an autologous anti-CD19 chimeric antigen receptor T-cell therapy) standard care (two three cycles investigator-selected, protocol-defined chemoimmunotherapy, followed by high-dose chemotherapy...
In a phase I study of autologous chimeric antigen receptor (CAR) anti-LeY T-cell therapy acute myeloid leukemia (AML), we examined the safety and postinfusion persistence adoptively transferred T cells. Following fludarabine-containing preconditioning, four patients received up to 1.3 × 109 total cells, which 14–38% expressed CAR. Grade 3 or 4 toxicity was not observed. One patient achieved cytogenetic remission whereas another with active had reduction in peripheral blood (PB) blasts third...
The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab a bispecific antibody that recruits T cells to tumor cells.In the phase 2 part of 1-2 study, we enrolled DLBCL who had received at least two lines therapy previously. Patients pretreatment obinutuzumab mitigate cytokine release syndrome, followed by fixed-duration glofitamab monotherapy (12 cycles total). primary end point was complete response according assessment an independent...
Glofitamab is a T-cell-engaging bispecific antibody possessing novel 2:1 structure with bivalency for CD20 on B cells and monovalency CD3 T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data single-agent glofitamab, obinutuzumab pretreatment (
In an analysis of the primary outcome this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), autologous anti-CD19 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longer event-free survival than those standard care. Data were needed on longer-term outcomes. Download a PDF Research Summary. we randomly assigned in 1:1 ratio to receive either axi-cel care (two three cycles...
High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study (ClinicalTrials.gov NCT03761056) we evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as part of treatment in 40 patients high-risk LBCL. This trial completed accrual. The primary outcome was complete response rate (CRR). Secondary were objective (ORR), duration (DOR),...
Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved diffuse large lymphoma at least two treatment lines.
Abstract CAR T-cell product quality and stemness (Tstem) are major determinants of in vivo expansion, efficacy, clinical response. Prolonged ex culturing is known to deplete Tstem, affecting outcome. YTB323, a novel autologous CD19-directed therapy expressing the same validated as tisagenlecleucel, manufactured using next-generation platform <2 days. Here, we report preclinical development preliminary data YTB323 adults with relapsed/refractory diffuse large B-cell lymphoma (r/r...
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of phase 2 ELARA trial reported high response rates and excellent safety profile patients extensively pretreated r/r FL. Here, we report longer-term efficacy, safety, pharmacokinetic, exploratory biomarker analyses after median follow-up 29 months (interquartile range, 22.2-37.7). As March 2022, 97 FL (grades...
Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is a devastating complication; the optimal prophylactic strategy remains unclear. We performed multicentre, retrospective analysis of patients with DLBCL high risk for CNS as defined by two or more of: multiple extranodal sites, elevated serum LDH and B symptoms involvement specific high-risk anatomical sites. compared three different strategies CNS-directed therapy: intrathecal (IT) methotrexate (MTX) (R)-CHOP...
Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis ≥65 years in ZUMA-7.
PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There no consensus regarding the optimal approach to prophylaxis. This study was designed determine whether high-dose methotrexate (HD-MTX) effective at preventing in patients high risk this complication. PATIENTS AND METHODS Patients age 18-80 years with lymphoma and progression, treated curative-intent anti–CD20-based chemoimmunotherapy, were included international, retrospective,...
7008 Background: Glofitamab, a bispecific antibody with novel 2:1 (CD20:CD3) format, engages and redirects T cells to eliminate malignant B cells. In Phase I/II study (NCT03075696), fixed-duration glofitamab monotherapy showed high, durable complete responses (CR) manageable safety in patients (pts) heavily pretreated R/R MCL (Phillips et al. ASH 2022). We report updated efficacy data for pts MCL. Methods: Pts received obinutuzumab pretreatment (Gpt; 1000mg or 2000mg) 7 days before their...
Cutaneous T-cell lymphomas (CTCL) are relatively rare with an annual incidence of approximately 0.2 to 0.8/100,000 and comprise a variety clinical entities; mycosis fungoides or its leukemic variant Sezary syndrome account for the majority cases. Advanced-stage disease is typically treated bexarotene (a retinoid), interferon, conventional chemotherapeutic agents, but relapses inevitable. Histone deacetylase inhibitors, which modify epigenome, attractive addition armamentarium. On basis 2...